| License: Creative Commons Attribution Non-commercial 4.0 PDF - Published Version (809kB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-523146
- DOI to cite this document:
- 10.5283/epub.52314
Abstract
Background and Objectives Defibrotide is approved to treat severe veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after haematopoietic cell transplantation in patients aged > 1 month in the European Union and for VOD/SOS with renal/pulmonary dysfunction post-haematopoietic cell transplantation in the United States. This meta-analysis estimated the incidence and risk of VOD/SOS ...

Owner only: item control page